Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365637 | 0.90 | PIM2 (0.35) | BTKPIM3PIM2GSK3BDYRK1A | |
| SCHEMBL17618714 | 0.88 | PRMT5 (0.40) | BTKPIM3PIM2GSK3BDYRK1A | |
| SCHEMBL19703416 | 0.88 | CNR2 (0.35) | BTKGSK3BDYRK1AFGFR4MAP3K12 | |
| SCHEMBL19365385 | 0.88 | CNR2 (0.35) | BTKGSK3BDYRK1AFGFR4MAP3K12 | |
| SCHEMBL17618633 | 0.87 | GRM5 (0.39) | BTKPIM3PIM2GSK3BDYRK1A | |
| SCHEMBL17618686 | 0.87 | GSK3B (0.37) | BTKPIM3PIM2GSK3BDYRK1A | |
| SCHEMBL17618661 | 0.86 | PIM3 (0.44) | BTKPIM3PIM2GRM5FAAH | |
| SCHEMBL17618606 | 0.86 | PIK3C3 (0.40) | BTKPIM3PIM2GSK3BDYRK1A | |
| SCHEMBL16238017 | 0.85 | TRPV1 (0.39) | PIM3PIM2DYRK1A | |
| SCHEMBL16238662 | 0.85 | TRPV1 (0.39) | PIM3PIM2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | BTK 678/4885PIM3 3489/4885PIM2 3242/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | BTK 678/4885PIM3 3489/4885PIM2 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.